NDAINJECTIONINJECTABLE
Approved
Mar 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUROMAX (doxacurium chloride) is an injectable neuromuscular blocking agent approved in 1991 for use during anesthesia and surgery. It works by competitively blocking acetylcholine at the neuromuscular junction, causing muscle paralysis. The drug is administered intravenously to facilitate intubation and surgical procedures.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely in maintenance mode, focused on defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NUROMAX offers limited career growth prospects given the product's approaching loss of exclusivity and zero linked job openings. This role is best suited for professionals seeking stable, routine commercial management of a legacy asset rather than high-impact innovation or career acceleration.
Brand ManagerField Sales Representative
Worked on NUROMAX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.